KR20210041571A - 역형성 림프종 키나아제 억제제와 조합하여 egf/egfr 경로를 억제하기 위한 방법 및 조성물 - Google Patents

역형성 림프종 키나아제 억제제와 조합하여 egf/egfr 경로를 억제하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20210041571A
KR20210041571A KR1020217004498A KR20217004498A KR20210041571A KR 20210041571 A KR20210041571 A KR 20210041571A KR 1020217004498 A KR1020217004498 A KR 1020217004498A KR 20217004498 A KR20217004498 A KR 20217004498A KR 20210041571 A KR20210041571 A KR 20210041571A
Authority
KR
South Korea
Prior art keywords
alk
once
antibody
egf
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217004498A
Other languages
English (en)
Korean (ko)
Inventor
에릭 돈트
빌라 미구엘 엔젤 몰리나
Original Assignee
인3바이오 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인3바이오 리미티드 filed Critical 인3바이오 리미티드
Publication of KR20210041571A publication Critical patent/KR20210041571A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001131—Epidermal growth factor [EGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217004498A 2018-08-07 2019-08-07 역형성 림프종 키나아제 억제제와 조합하여 egf/egfr 경로를 억제하기 위한 방법 및 조성물 Pending KR20210041571A (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862715351P 2018-08-07 2018-08-07
US62/715,351 2018-08-07
US201862727056P 2018-09-05 2018-09-05
US62/727,056 2018-09-05
US201862748772P 2018-10-22 2018-10-22
US62/748,772 2018-10-22
US201862760529P 2018-11-13 2018-11-13
US62/760,529 2018-11-13
US201962822290P 2019-03-22 2019-03-22
US62/822,290 2019-03-22
PCT/IB2019/000905 WO2020030977A2 (en) 2018-08-07 2019-08-07 Methods and compositions for inhibition of egf/egfr pathway in cobination with anaplastic lymphoma kinase inhibitors

Publications (1)

Publication Number Publication Date
KR20210041571A true KR20210041571A (ko) 2021-04-15

Family

ID=68425157

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217004498A Pending KR20210041571A (ko) 2018-08-07 2019-08-07 역형성 림프종 키나아제 억제제와 조합하여 egf/egfr 경로를 억제하기 위한 방법 및 조성물

Country Status (11)

Country Link
US (1) US12257245B2 (https=)
EP (1) EP3833384A2 (https=)
JP (1) JP2021534094A (https=)
KR (1) KR20210041571A (https=)
CN (1) CN112996534B (https=)
AU (1) AU2019319109A1 (https=)
BR (1) BR112021002145A2 (https=)
CA (1) CA3108236A1 (https=)
IL (1) IL280632A (https=)
MX (1) MX2021001398A (https=)
WO (1) WO2020030977A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112300284B (zh) * 2020-12-29 2021-04-06 慈达(广州)生物技术有限公司 核酸筛选结合抗体检测用于癌症检测中的用途及其制备的试剂盒
WO2022256360A1 (en) * 2021-06-02 2022-12-08 Neuvogen, Inc. Tumor cell vaccines
WO2023059801A1 (en) * 2021-10-06 2023-04-13 The Regents Of The University Of Colorado, A Body Corporate Biomarkers for egfr-mediated resistance in oncogene-driven cancers and methods of treating, preventing, and/or ameliorating oncogene-driven cancers
KR102685187B1 (ko) 2021-10-15 2024-07-16 제이투에이치바이오텍 (주) Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도
MX2024005177A (es) * 2021-10-28 2024-08-27 In3Bio Ltd Métodos de uso de anticuerpos anti-fce para aumentar la actividad de los inhibidores de braf y kras.
TW202339767A (zh) * 2022-01-18 2023-10-16 大陸商齊魯製藥有限公司 螺環芳基磷氧化物與抗ｅｇｆｒ抗體的聯用藥物組合物及其用途
WO2024017352A1 (zh) * 2022-07-22 2024-01-25 四川大学 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒
WO2024249331A1 (en) * 2023-05-26 2024-12-05 The Board Of Regents Of The University Of Texas System Combined rtk and alk inhibition in rtk driven cancers
KR20250120789A (ko) 2024-02-02 2025-08-11 제이투에이치바이오텍 (주) E3 리가제 리간드 화합물, alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPH10147952A (ja) 1996-11-18 1998-06-02 Komatsu Ltd ブルドーザのドージング装置
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
AU2012312515A1 (en) * 2011-09-19 2014-03-13 Genentech, Inc. Combination treatments comprising c-met antagonists and B-raf antagonists
JP6016953B2 (ja) 2012-03-06 2016-10-26 セファロン、インク． 二重のａｌｋおよびｆａｋ阻害剤としての縮合二環式２，４−ジアミノピリミジン誘導体
CA2882759C (en) * 2012-08-31 2018-11-20 The Regents Of The University Of Colorado Detection of the ntrk1-mprip gene fusion for cancer diagnosis
WO2015148904A1 (en) * 2014-03-28 2015-10-01 Driver Group Methods for predicting egfr tyrosine kinase inhibitor efficacy
KR102359214B1 (ko) * 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
US12595297B2 (en) 2015-05-12 2026-04-07 In3Bio Ltd. Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors
KR20180011839A (ko) * 2015-06-08 2018-02-02 제넨테크, 인크. 항-ox40 항체를 이용한 암의 치료 방법
HK1251474A1 (zh) * 2015-06-08 2019-02-01 豪夫迈‧罗氏有限公司 使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法
CN111246878A (zh) 2017-07-18 2020-06-05 因斯瑞拜奥有限公司 合成蛋白及其治疗用途
RU2654695C1 (ru) 2017-07-28 2018-05-22 Акционерное Общество "Р-Фарм" (Ао "Р-Фарм") 8-(1-{ 4-{ (5-Хлор-4-{ (2-(диметилфосфорил)фенил)амино} пиримидин-2-ил)амино)-3-метоксифенил} пиперидин-4-ил)-1-метил-1,8-диазаспиро(4.5)декан-2-он и его фармацевтически приемлемые соли в качестве модулятора ALK и EGER, предназначенные для лечения рака

Also Published As

Publication number Publication date
WO2020030977A2 (en) 2020-02-13
CN112996534A (zh) 2021-06-18
CA3108236A1 (en) 2020-02-13
BR112021002145A2 (pt) 2021-12-14
US12257245B2 (en) 2025-03-25
CN112996534B (zh) 2025-11-18
US20200046690A1 (en) 2020-02-13
MX2021001398A (es) 2021-08-16
JP2021534094A (ja) 2021-12-09
AU2019319109A1 (en) 2021-02-25
WO2020030977A3 (en) 2020-06-18
IL280632A (en) 2021-03-25
EP3833384A2 (en) 2021-06-16

Similar Documents

Publication Publication Date Title
CN112996534B (zh) 结合间变性淋巴瘤激酶抑制剂进行egf/egfr通路抑制的方法和组合物
JP2020511993A (ja) ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ−２及びＥｒｂＢ３結合二重特異性抗体
JP2021138704A (ja) 神経膠芽腫の治療のための併用療法
TWI885529B (zh) 抗體-藥物結合物之用途
TW201138819A (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
CN112512576A (zh) PD-1/PD-L1、TGFβ和DNA-PK联合抑制用于治疗癌症
CN103025353A (zh) 治疗方法
US20260070993A1 (en) Treatment of Non-Small Cell Lung Cancer with EGFR Mutations
JP2024041781A (ja) チロシンキナーゼ阻害剤と併用してｅｇｆ／ｅｇｆｒ経路を抑制する方法および組成物
WO2020249018A1 (zh) 治疗驱动基因阳性肺癌的联用药物组合物
KR20240082379A (ko) 암 치료 방법 및 이의 약제학적 조성물
JP2025507694A (ja) 結腸直腸癌に対する組み合わせ療法
KR20150079599A (ko) 네트린-1 방해 약물 및 화학요법 약물을 조합한 치료
CN114615995A (zh) PD-1、TGFβ和ATM联合抑制与放疗联合用于癌症治疗
WO2024214685A1 (ja) 抗ｂ７－ｈ３抗体－薬物コンジュゲートとａｔｒ阻害剤又はａｔｍ阻害剤との組み合わせ
EP4422757A1 (en) Methods of using anti-egf antibodies to augment the activity of braf and kras inhibitors
JP2024534935A (ja) エフリンｂ２発現を用いたがんの診断方法
US20190358320A1 (en) Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
US20260115267A1 (en) Methods of using anti-egf antibodies to augment the activity of braf and kras inhibitors
TWI920018B (zh) 抗ｈｅｒ３抗體-藥物結合物用於治療ｈｅｒ３突變癌之醫藥的用途
CN119585616A (zh) 治疗nsclc的生物标志物和方法
CN118176017A (zh) 治疗肿瘤的联用药物
HK40021172A (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902